Liver Disease

Approximately 14% of the U.S. population lives in rural areas, where access to health care may be limited by insurance coverage, geography and infrastructure, and provider shortages, according to HHS.

Injectable naltrexone had a more favorable gastrointestinal and liver safety profile compared with other medications for alcohol use disorder, according to a research letter published in Clinical Gastroenterology and Hepatology.

Eight years ago, Ocaliva was a prospective lifesaver for patients with primary biliary cholangitis who failed to adequately respond to first-line ursodeoxycholic acid. However, the once-promising drug now finds itself struggling to deliver.

Diabetes and prediabetes were significantly associated with decreased life expectancy and increased risk for all-cause, cardiovascular disease and cancer mortality among Chinese adults, according to findings published in Diabetes Care.

SAN DIEGO — Glucagon-like peptide-1 receptor agonists may help alleviate risk for adverse liver outcomes, particularly hepatic decompensation, among patients with type 2 diabetes and alcohol-associated liver disease.

Recent advancements have been made in the treatment of primary biliary cholangitis, particularly for patients who do not respond adequately to first-line treatment.

PHILADELPHIA — The rate of alcohol-associated liver disease among women is the rise and physicians must keep it in mind when discussing medical history with their female patients, according to a review presented here.

Significant differences in alcohol use, alcohol-related mortality and liver transplant rate by race and ethnicity underscore the need for “tailored approaches to managing” alcohol-related liver disease in the U.S., according to a researcher.

The FDA granted breakthrough designation to Sagimet Biosciences’ denifanstat for the treatment of patients with metabolic dysfunction-associated steatohepatitis and moderate to advanced fibrosis, according to a company press release.

Sodium-glucose cotransporter-2 inhibitors showed similar hepatic effectiveness to glucagon-like peptide-1 receptor agonists, especially among women and younger patients, in metabolic dysfunction-associated steatotic liver disease.